Monopar Therapeutics (MNPR) Assets Average (2018 - 2025)

Monopar Therapeutics has disclosed Assets Average across 8 years of filings, most recently posting $142.5 million for Q4 2025.

• Assets Average for Q4 2025 came in at $142.5 million, up 329.34% year-over-year; the trailing twelve-month figure through Dec 2025 was $142.5 million (up 329.34% YoY), and the FY2025 annual result was $100.5 million, up 197.19% from the prior year.
• Assets Average came in at $142.5 million for Q4 2025 at Monopar Therapeutics, up from $99.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $142.5 million in Q4 2025 to a low of $6.6 million in Q3 2024.
• The 5-year median for Assets Average is $18.3 million (2022), against an average of $30.4 million.
• Across the five-year window, Assets Average sank 42.4% in 2023 and surged 1394.88% in 2025, its largest moves.
• Monopar Therapeutics' Assets Average stood at $21.5 million in 2021, then plunged by 35.7% to $13.8 million in 2022, then tumbled by 42.4% to $8.0 million in 2023, then soared by 316.36% to $33.2 million in 2024, then surged by 329.34% to $142.5 million in 2025.
• The last three Assets Average figures came in at $142.5 million (Q4 2025), $99.0 million (Q3 2025), and $54.5 million (Q2 2025), per Business Quant data.